Allergy Therapeutics - Grant of Options under Long Term Incentive Scheme

Allergy Therapeutics

28/01/2026 16:48

RNS Number : 7908Q

Allergy Therapeutics PLC

28 January 2026

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company" or the "Group")

 

Grant of Options under Long Term Incentive Scheme

 

28 January 2026: Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces that on 27 January 2026 it granted share option awards to key members of Allergy Therapeutics' management team including certain of its persons discharging managerial responsibilities ("PDMRS").

 

The Board has granted options to encourage long-term value creation for the Company's shareholders, and so that the individuals identified as key people to lead the business into the future are appropriately incentivised in a manner that aligns with the interests of the Group's stakeholders.

 

Vesting is conditional on the satisfaction of performance criteria over a three-year period. Vesting of 70 per cent. of the award subject to Adjusted EBITDA* performance and vesting of the remaining 30 per cent. of the award is subject to share price performance.

 

The following awards have been made in accordance with the Group LTIP:

 

Name
Title
Number of share options granted
Resultant
number of share options held
Performance period
Vesting Date
Exercise price
Number of
Ordinary Shares
held
Manuel Llobet
Chief Executive Officer
5,409,724
142,578,024
3 years commencing 1 July 2025
30 June 2028
£0.001
5,001,200
Shaun Furlong
Chief Financial Officer
2,489,627
21,704,724
3 years commencing 1 July 2025
30 June 2028
£0.001
1,507

 

The number of Ordinary Shares stated above is the maximum number that could be issued to each PDMR upon full satisfaction of the performance conditions attached to the awards.

 

The Group's Remuneration Committee will review the performance conditions at periodic intervals to ensure they remain appropriate. As a result of any such review, the Committee will retain discretion to amend the conditions where appropriate having regard to overall Company performance and wider stakeholder experience.

 

Following the above grants of options, the Company has options outstanding over 365,205,852 ordinary shares, representing 5.95% of the Company's current issued share capital.

 

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

 

*Adjusted EBITDA means earnings before interest, taxes, depreciation and amortisation adjusted to exclude the impact of R&D expenditure, exceptional items, equity settled long term incentive plans and gains or losses arising on fundraising activities. The Committee may, in its absolute discretion, make further adjustments to the Adjusted EBITDA figure disclosed in the Company's audited consolidated accounts for the relevant financial year, so that the Adjusted EBITDA figure fairly reflects underlying Group financial performance. Adjustments may include, but are not limited to, the cost of long-term strategic investments, approved after the relevant performance condition was set, with a short-term negative impact on Adjusted EBITDA in the relevant financial year. Such adjustments will be applied on a logical, transparent and consistent basis. 

 

-  ENDS -

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash/Giles Balleny/Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

 

ICR Healthcare

Mary-Jane Elliott/David Daley/Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries and branches in nine major European countries and via distribution agreements in an additional four countries. For more information, please see www.allergytherapeutics.com.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the Market Abuse Regulations

 

1
Details of the persons discharging managerial responsibilities / person closely associated
a)
Name
Manuel Llobet
2
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Allergy Therapeutics plc
b)
LEI
213800PQ7AHK7KGVOE23
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares of 0.1 pence each
Identification code
GB00B02LCQ05
b)
Nature of the transaction
Grant of options
c)
Price(s) and volume(s)
Exercise Price per share
Volume
£0.001
5,409,724
d)
Aggregated information
- Aggregated volume
- Price
See 4c) above
e)
Date of the transaction
27 January 2026
f)
Place of the transaction
Outside a trading venue

 

 

1
Details of the persons discharging managerial responsibilities / person closely associated
a)
Name
Shaun Furlong
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Allergy Therapeutics plc
b)
LEI
213800PQ7AHK7KGVOE23
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares of 0.1 pence each
Identification code
GB00B02LCQ05
b)
Nature of the transaction
Grant of options
c)
Price(s) and volume(s)
Exercise Price per share
Volume
£0.001
2,489,627
d)
Aggregated information
- Aggregated volume
- Price
See 4c) above
e)
Date of the transaction
27 January 2026
f)
Place of the transaction
Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHBPMFTMTITBFF